UniProt Q6PHR2 · PDB · AlphaFold · Substrate: Casein · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 94.6% | 5.4% | 78.23 | 0.534 |
| 2 | Gilteritinib | 93.8% | 6.2% | 88.97 | 0.506 |
| 3 | Brigatinib | 78.7% | 21.3% | 82.96 | 0.513 |
| 4 | Fostamatinib | 74.4% | 25.6% | 96.74 | 0.613 |
| 5 | Pacritinib | 70.2% | 29.8% | 88.64 | 0.452 |
| 6 | Midostaurin | 65.3% | 34.7% | 78.64 | 0.500 |
| 7 | Sunitinib | 61.2% | 38.8% | 91.73 | 0.524 |
| 8 | Vemurafenib | 59.1% | 40.9% | 96.49 | 0.598 |
| 9 | Dabrafenib | 54.4% | 45.6% | 94.74 | 0.633 |
| 10 | Baricitinib | 52.6% | 47.4% | 97.99 | 0.616 |
| 11 | Repotrectinib | 48.8% | 51.2% | 84.21 | 0.608 |
| 12 | Bosutinib | 44.5% | 55.5% | 87.22 | 0.555 |
| 13 | Defactinib | 41.0% | 59.0% | 92.68 | 0.450 |
| 14 | Axitinib | 40.0% | 60.0% | 93.23 | 0.688 |
| 15 | Fedratinib | 35.7% | 64.3% | 96.21 | 0.576 |
| 16 | Nintedanib | 25.7% | 74.3% | 90.23 | 0.608 |
| 17 | Upadacitinib | 25.3% | 74.7% | 97.98 | 0.663 |
| 18 | Abrocitinib | 25.2% | 74.8% | 99.50 | 0.581 |
| 19 | Crizotinib | 22.0% | 78.0% | 91.39 | 0.581 |
| 20 | Erlotinib | 19.1% | 80.9% | 99.75 | 0.695 |
Paralog block
ULK1, ULK2, ULK3
EMT expression
- Mesenchymal log2(TPM+1): 3.85
- Epithelial log2(TPM+1): 4.69
- Fold change: -0.84
- Status: No significant change
Selectivity landscape vs inhibition on ULK3
Each point is one of the 92 approved drugs; color = inhibition % on ULK3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…